25.11.2024 07:00:02 CET | Thor Medical ASA | Non-regulatory press releases

Stockholm, 25 November 2024: Thor Medical ASA (Oslo Børs: TRMED), a leading
emerging supplier of alpha-emitters for next-generation precision cancer
treatment, today presents its long-term vision to transform cancer care and its
strategic priorities for the coming years at a Capital Markets Update (CMU) in
Stockholm.

"Thor Medical aims to become a world-leading supplier of alpha-emitters for
cancer therapies and we have made significant progress towards realizing our
ambitions this year. The number of clinical trials with radiopharmaceuticals for
cancer treatment is at an all-time high, and successful product launches will
generate high and growing demand for high-quality radioisotopes such as our
Thorium-228, Radium-224, and Pb-212. Right now we are seeing the beginning of a
transformative era in cancer treatment based on next-generation precision
therapies," says CEO Jasper Kurth.

Thor Medical key highlights in 2024:

 * Successfully completed and commissioned pilot facilities at Herøya, on-time
   and on-budget and with all required authorizations secured?
 * Secured strategic five-year supply agreement with ARTBIO for Thorium-228
 * Shipped the first batch of Thorium-228 from the recently opened pilot
   facilities
 * Signed three-year supply agreement with globally leading pharmaceutical
   company for Pb-212 for use in pre-clinical studies?
 * Developed strong partnerships with feedstock suppliers to ensure consistent
   and reliable supply of raw materials
 * Completed concept study for 'AlphaOne' commercial plant with an estimated
   capital requirement of approximately USD 30 million?

The CMU will be held at Carnegie's premises in Stockholm, Sweden, and can be
followed live physically at the premises or digitally through a webcast by
registering at the following link: https://tinyurl.com/2jx2hxzp

Agenda: 

 * Introduction - Jasper Kurth, CEO | Thor Medical
 * Targeted Alpha Therapies in Cancer Treatment - Professor Jane Sosabowski, PhD
   | Barts Cancer Institute Queen Mary University of London
 * Role of Isotope Supply for Targeted Alpha Therapies - Emanuele Ostuni, PhD,
   CEO | ARTBIO
 * Thor Medical enabling next-generation precision cancer treatments - Jasper
   Kurth CEO and Brede Ellingsæter, CFO | Thor Medical

Location: Regeringsgatan 56, 111 56 Stockholm

Date & Time: 25 November 2024, 13:00-15:00 CET

It will be possible to ask questions both from the audience and via webcast
during the presentations.



CONTACTS

 * Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
   brede.ellingseter@thormedical.com 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visitwww.thormedical.no - https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18334453/5335/Download%20announce
ment%20as%20PDF.pdf

Capital Markets Update Presentation 25 November 2024.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18334453/5334/Capital%20Markets%2
0Update%20Presentation%2025%20November%202024.pdf